Table 1.
Characteristics of Included and Parent Studies
| First Author and Year of Publication | Journal | Study Type | Duration (Weeks) | Drug 1 (n) | Drug 2 (n) | Placebo- Controlled (n) | Age | Duration of OAB Symptoms | Frequency (Inclusion) | Urgency (Inclusion) | Percent Females %(n) | Location | Country | JADAD Criteria Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Szonyi (1995)(Szonyi et al., 1995) | Age Ageing | RCT | 6 | Oxybutynin IR (28) | -- | Yes (26) | ≥70 | Not noted | “Frequency” | “Urgency” | 93.3 (56) | Ambulatory | England | 4 |
| Malone-Lee (2001)(Malone-Lee et al., 2001) | J Am Geriatr Soc | RCT | 4 | Tolterodine IR (134) | -- | Yes (43) | ≥65 | Not noted | ≥8/24 hours | “Urgency” | 65.0 (115) | Ambulatory | Multinational | 3 |
| Zinner (2002)(Zinner et al., 2002) | J Am Geriatr Soc | SA of RCT | -- | Tolterodine ER (214) | -- | Yes (223) | ≥65 | -- | -- | -- | 74.4 (325) | -- | -- | -- |
| Van Kerrebroeck (2001)(Van Kerrebroeck et al., 2001) | Urology | -- | 12 | -- | ≥6 months | ≥8/24 hours | ≥5 UUI episodes/week | -- | Not Noted | Multinational | 5 | |||
| Sand (2004)(Sand et al., 2004) | Int Urogynecol J | SA of RCT | -- | Oxybutynin ER (51) | Tolterodine IR (60) | No | ≥65 | -- | -- | -- | 100 (111) | -- | -- | -- |
| Appell (2001)(Appell et al., 2001) | Mayo Clin Proc | -- | 12 | -- | Not noted | ≥10/24 hours | 7–50 UUI episodes/week | -- | Not Noted | USA | 4 | |||
| Foote (2005)*(Foote et al., 2005) | Eur Urol | Pooled RCT | -- | Darifenacin (207) | -- | Yes (110) | ≥65 | -- | -- | -- | 77.6 (246) | -- | -- | -- |
| Wagg (2006)(Wagg et al., 2006) | Am J Geriatr Pharmacother | Pooled RCT | . | Solifenacin (623) | Yes (422) | ≥65 | -- | -- | -- | 74.7(781) | -- | -- | -- | |
| Cardozo (2004)(Cardozo et al., 2004) | J Urol | -- | 12 | -- | ≥3 months | ≥8/24 hours | ≥1 urge or incontinent episode/day | -- | Not Noted | Multinational | 3 | |||
| Chapple (2004)(Chapple et al., 2004b) | BJU Int | -- | 12 | -- | ≥3 months | ≥8/24 hours | ≥1 urge or incontinent episode/day | -- | Not Noted | Multinational | 3 | |||
| Chapple (2004)(Chapple et al., 2004a) | BJU Int | -- | 4 | -- | Not Noted | ≥8/24 hours | ≥1 urge or incontinent episode/day | -- | Not Noted | Not Noted | 3 | |||
| Chapple (2005)(Chapple et al., 2005) | Eur Urol | -- | 12 | -- | ≥3 months | ≥8/24 hours | ≥1 urge or incontinent episode/day | -- | Not Noted | Not Noted | 5 | |||
| Minassian (2007)(Minassian et al., 2007) | J Obstet Gynaecol Can | RCT | 12 | Oxybutynin ER (38) | Oxybutynin IR (30) | No | ≥65 | Not noted | ≥8/24 hours | ≥1 urge episode/week | 100 (72) | Ambulatory | Canada | 2 |
| Chapple (2007)(Chapple et al., 2007a) | Curr Med Res Opin | RCT | 12 | Darifenacin (266) | -- | Yes (133) | ≥65 | ≥6 months | ≥10/24 hours | ≥1 UUI episodes/day | 76.6 (306) | Ambulatory | Multinational | 5 |
| Lackner (2008)(Lackner et al., 2008) | J Am Geriatr Soc | RCT | 4 | Oxybutynin ER (26) | -- | Yes (24) | ≥ 65 | Not noted | ≥ 4/8 hours | Nocturia > 2 night; Staff or patient reported urgency | 100 (50) | LTCF | USA | 5 |
| Kraus (2010)(Kraus et al., 2010b) | Urology | Pooled RCT | -- | Fesoterodine (370) | -- | Yes (178) | ≥65 | -- | -- | -- | 70.9 (389) | -- | -- | -- |
| Chapple (2007)(Chapple et al., 2007b) | Eur Urol | . | 12 | -- | ≥6 months | ≥8/24 hours | ≥6 urgency episodes or ≥3 UUI episodes/day | -- | Not Noted | Multinational | 3 | |||
| Nitti (2007)(Nitti et al., 2007) | J Urol | . | 12 | -- | ≥3 months | ≥8/24 hours | ≥1 urge episodes and/or ≥1 UUI episodes/day | -- | Not Noted | USA | 4 | |||
| Herschorn (2011)(Herschorn et al., 2011) | Curr Med Res Opin | SA of RCT | -- | Solifenacin (27) | Oxybutynin IR (30) | No | ≥65 | -- | -- | -- | 77.2 (44) | -- | -- | -- |
| Herschorn (2010)(Herschorn et al., 2010a) | J Urol | . | 8 | -- | Not noted | ≥8/24 hours | >1 urge episode/day | -- | Not Noted | Canada | 5 | |||
| Sand (2011)(Sand et al., 2011) | BJU Int | Pooled RCT | . | Trospium ER (85) | Yes (58) | ≥75 | -- | -- | -- | 73.4 (105) | -- | -- | -- | |
| Dmochowski (2008)(Dmochowski et al., 2008) | Urology | -- | 12 | -- | ≥6months | ≥10/24 hours | ≥1 severe urgency/day and ≥1 UUI episode/day | -- | Not Noted | USA | 3 | |||
| Staskin (2007)(Staskin et al., 2007) | J Urol | -- | 12 | -- | ≥6 months | ≥10/24 hours | ≥1 severe urgency/3 days or 1 UUI episode/day | -- | Not Noted | USA | 5 | |||
| DuBeau (2012)(DuBeau et al., 2012) | Neurol Urodyn | Pooled RCT | -- | Fesoterodine (546) | Tolterodine ER (586) | Yes (306) | ≥65 | -- | -- | -- | 78.4 (1128) | -- | -- | -- |
| Herschorn (2010)(Herschorn et al., 2010b) | BJU Int | -- | 12 | -- | ≥3 months | ≥8/24 hours | ≥1 UUI episodes/day | -- | Not Noted | Not noted | 5 | |||
| Kaplan (2011)(Kaplan et al., 2011) | BJU Int | -- | 12 | -- | ≥3 months | ≥8/24 hours | ≥1 UUI episodes/day | -- | Not Noted | Multinational | 5 | |||
| Wagg (2013)(Wagg et al., 2013) | J Am Geriatr Soc | RCT | 12 | Fesoterodine (392) | -- | Yes (393) | ≥65 | ≥3 months | ≥8/24 hours | ≥3 urge episode/day | 53.2 (418) | Ambulatory | Multinational | 5 |
| Wagg (2014)(Wagg et al., 2014) | Age Ageing | Pooled RCT | . | Tolterodine ER (192) | -- | Yes (521) | ≥65 | -- | -- | -- | 65.2 (465) | -- | -- | -- |
| Khullar (2013)(Khullar et al., 2013) | Eur Urol | -- | 12 | -- | ≥3 months | ≥8/24 hours | ≥1 urge episode/day | -- | Not Noted | Multinational | 4 | |||
| Nitti (2013)(Nitti et al., 2013) | J Urol | -- | 12 | -- | ≥3 months | ≥8/24 hours | ≥1 urge episode/day | -- | Not Noted | Multinational | 5 | |||
| Herschorn (2013)(Herschorn et al., 2013) | Urology | -- | 12 | -- | ≥3 months | ≥8/24 hours | ≥3 urge episode/day | -- | Not Noted | Multinational | 3 | |||
| DuBeau (2014)(Dubeau et al., 2014) | J Urol | RCT | 12 | Fesoterodine (293) | -- | Yes (283) | ≥65 | ≥3 months | ≥8/24 hours | UUI 2–15 episodes/day | 82.0 (461) | Not Noted | USA | 5 |
*
unable to obtain parent studies
ER = extended release; IR = immediate release; LTCF = long-term care facility; RCT = Randomized, Controlled Trial; SA = sub-analysis; UUI = urge urinary incontinence; USA = United States of America
Under the “First Author and Year of Publication” columns, included studies are bolded and parent studies not bolded.